138 related articles for article (PubMed ID: 9069682)
21. [Attention deficit hyperactivity disorder in children].
Bervoets L
J Pharm Belg; 2002; 57(2):25-32. PubMed ID: 12053824
[No Abstract] [Full Text] [Related]
22. Licit and illicit use of medications for Attention-Deficit Hyperactivity Disorder in undergraduate college students.
Advokat CD; Guidry D; Martino L
J Am Coll Health; 2008; 56(6):601-6. PubMed ID: 18477513
[TBL] [Abstract][Full Text] [Related]
23. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline.
Pelham WE; Greenslade KE; Vodde-Hamilton M; Murphy DA; Greenstein JJ; Gnagy EM; Guthrie KJ; Hoover MD; Dahl RE
Pediatrics; 1990 Aug; 86(2):226-37. PubMed ID: 2196522
[TBL] [Abstract][Full Text] [Related]
24. [Prescribing ritalin in combined modality management of hyperactivity with attention deficit].
Bricard C; Boidein F
Encephale; 2001; 27(5):435-43. PubMed ID: 11760693
[TBL] [Abstract][Full Text] [Related]
25. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
[TBL] [Abstract][Full Text] [Related]
26. Pharmacotherapy of attention-deficit/hyperactivity disorder in adults.
Wender PH
J Clin Psychiatry; 1998; 59 Suppl 7():76-9. PubMed ID: 9680056
[TBL] [Abstract][Full Text] [Related]
27. Attention-deficit-hyperactivity disorder: an update.
Dopheide JA; Pliszka SR
Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
[TBL] [Abstract][Full Text] [Related]
28. Prolonged P300 latency in attention deficit hyperactivity disorder predicts poor response to imipramine.
Sangal JM; Sangal RB; Persky B
Clin Electroencephalogr; 1996 Oct; 27(4):191-201. PubMed ID: 9465283
[TBL] [Abstract][Full Text] [Related]
29. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
Medori R; Ramos-Quiroga JA; Casas M; Kooij JJ; Niemelä A; Trott GE; Lee E; Buitelaar JK
Biol Psychiatry; 2008 May; 63(10):981-9. PubMed ID: 18206857
[TBL] [Abstract][Full Text] [Related]
30. Stimulant treatment of adult attention-deficit/hyperactivity disorder.
Spencer T; Biederman J; Wilens T
Psychiatr Clin North Am; 2004 Jun; 27(2):361-72. PubMed ID: 15064002
[TBL] [Abstract][Full Text] [Related]
31. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder.
Fallu A; Richard C; Prinzo R; Binder C
Curr Med Res Opin; 2006 Dec; 22(12):2557-66. PubMed ID: 17166338
[TBL] [Abstract][Full Text] [Related]
32. Treatment of attention-deficit/hyperactivity disorder: overview of the evidence.
Brown RT; Amler RW; Freeman WS; Perrin JM; Stein MT; Feldman HM; Pierce K; Wolraich ML; ;
Pediatrics; 2005 Jun; 115(6):e749-57. PubMed ID: 15930203
[TBL] [Abstract][Full Text] [Related]
33. Effects of two doses of methylphenidate on simulator driving performance in adults with attention deficit hyperactivity disorder.
Barkley RA; Murphy KR; O'Connell T; Connor DF
J Safety Res; 2005; 36(2):121-31. PubMed ID: 15896352
[TBL] [Abstract][Full Text] [Related]
34. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
Biederman J; Mick E; Surman C; Doyle R; Hammerness P; Harpold T; Dunkel S; Dougherty M; Aleardi M; Spencer T
Biol Psychiatry; 2006 May; 59(9):829-35. PubMed ID: 16373066
[TBL] [Abstract][Full Text] [Related]
35. Developmental aspects of psychostimulant treatment in children and adolescents with attention-deficit/hyperactivity disorder.
Findling RL; Short EJ; Manos MJ
J Am Acad Child Adolesc Psychiatry; 2001 Dec; 40(12):1441-7. PubMed ID: 11765290
[TBL] [Abstract][Full Text] [Related]
36. Symposium: behavior modification by drugs. II. Psychological effects of stimulant drugs in children with minimal brain dysfunction.
Conners CK
Pediatrics; 1972 May; 49(5):702-8. PubMed ID: 4402496
[No Abstract] [Full Text] [Related]
37. Predictors of weight loss in children with attention deficit hyperactivity disorder treated with stimulant medication.
Schertz M; Adesman AR; Alfieri NE; Bienkowski RS
Pediatrics; 1996 Oct; 98(4 Pt 1):763-9. PubMed ID: 8885958
[TBL] [Abstract][Full Text] [Related]
38. The misuse and diversion of prescribed ADHD medications by college students.
Rabiner DL; Anastopoulos AD; Costello EJ; Hoyle RH; McCabe SE; Swartzwelder HS
J Atten Disord; 2009 Sep; 13(2):144-53. PubMed ID: 19448150
[TBL] [Abstract][Full Text] [Related]
39. Pharmacodynamics of pemoline in attention deficit disorder with hyperactivity.
Sallee FR; Stiller RL; Perel JM
J Am Acad Child Adolesc Psychiatry; 1992 Mar; 31(2):244-51. PubMed ID: 1564025
[TBL] [Abstract][Full Text] [Related]
40. Attention-deficit/hyperactivity disorder and sleep disorders in children.
Tsai MH; Huang YS
Med Clin North Am; 2010 May; 94(3):615-32. PubMed ID: 20451036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
